Patents Examined by Bo Peng
-
Patent number: 7427468Abstract: The present invention provides methods of using antibodies that bind a TSG101 protein to inhibit or reduce viral production. The invention also provides methods of using the TSG101 antibodies for the treatment of viral infections, including HIV infection. The invention further provides methods of detecting viral infected cells using TSG101 antibodies.Type: GrantFiled: October 1, 2003Date of Patent: September 23, 2008Assignee: Functional Genetics, Inc.Inventor: Limin Li
-
Patent number: 7410795Abstract: The invention is related to polynucleotide-based cytomegalovirus vaccines. In particular, the invention is plasmids operably encoding HCMV antigens, in which the naturally-occurring coding regions for the HCMV antigens have been modified for improved translation in human or other mammalian cells through codon optimization. HCMV antigens which are useful in the invention include, but are not limited to pp65, glycoprotein B (gB), IE1, and fragments, variants or derivatives of either of these antigens. In certain embodiments, sequences have been deleted, e.g., the Arg435-Lys438 putative kinase in pp65 and the membrane anchor and endocellular domains in gB. The invention is further directed to methods to induce an immune response to HCMV in a mammal, for example, a human, comprising delivering a plasmid encoding a codon-optimized HCMV antigen as described above.Type: GrantFiled: December 19, 2003Date of Patent: August 12, 2008Assignee: Vical IncorporatedInventors: Gary G. Hermanson, Andrew J. Geall, Mary Kopke Wloch
-
Patent number: 7396914Abstract: Codon-optimized nucleic acids, polypeptides, and antibodies are described herein.Type: GrantFiled: August 4, 2004Date of Patent: July 8, 2008Assignee: University of MassachusettsInventors: Donna Ambrosino, Hector Hernandez, Thomas Greenough, Katherine Luzuriaga, Mohan Somasundaran, Gregory J. Babcock, William D. Thomas, Jr., John Sullivan
-
Patent number: 7393933Abstract: A monoclonal antibody that is capable of binding specifically to wild type HBsAg and to at least two mutant forms of HBsAg may be used in an improved immunoassay for the detection of both escape mutants and wild type HBsAg and may be used for passive immunisation against HBV.Type: GrantFiled: April 25, 1997Date of Patent: July 1, 2008Inventors: Richard Seton Tedder, Samreen Ijaz, Ruth Bridget Ferns
-
Patent number: 7374763Abstract: Protein sequences encoding antigenized antibodies for treatment of foot-and-mouth disease (FMD) or foot-and-mouth disease virus (FMDV) of swine is provided. The antigenized antibodies are created from the grafting of peptide epitopes derived from FMDV into swine antibody CDR loops. FMDV peptide epitopes are cloned by PCR from VP1 gene of FMDV. The overlapping PCR method is used to insert the FMDV peptide epitopes into the CDR regions of swine immnuoglobulin heavy and light chains genes. The resulting antigenized antibody genes were cloned into mammalian expression vector. The plasmids are transfected into CHO or myeloma cells. The stable transfectant cell line was selected for high yield of the desired protein antibodies.Type: GrantFiled: August 9, 2004Date of Patent: May 20, 2008Assignee: The Hong Kong University of Science & TechnologyInventor: Xie Yong
-
Patent number: 7374766Abstract: The present invention is related to the branch of medicine, particularly to the new formulations of vaccine antigens. The technical objective pursued with the present invention is, precisely, the development of formulations that are able to enhance the immune response to mucosally administered antigens, minimising the number of compounds in the formulation and generating strong mucosal and systemic responses through a synergic interaction between the antigens in the formulation. These formulations enable: a) to broaden the spectrum of the anti-hepatitis B immune response, containing as main compounds HBsAg and HBcAg, b) to enhance the response against HBsAg with a viral nucleocapsid c) to generate combined vaccines through the mucosal route with HBsAg as a central antigen. Stabilizers and preservatives can be introduced. The formulations of this invention can be applied in the pharmaceutical industry as human or veterinary vaccine formulations.Type: GrantFiled: December 1, 1999Date of Patent: May 20, 2008Assignee: Centro de Ingenieria Genetic y BiotechnologiaInventors: Julio César Aguilar Rubido, Daniel O. Palenzuela Gardón, Verena L. Muzio González, Gerardo E. Guillén Nieto, Eduardo Pentón Arias, Dagmara Pichardo Díaz, Enrique Iglesias Perez
-
Patent number: 7371837Abstract: The present invention provides the complete genomic sequence of a novel human coronavirus, coined as human coronavirus-HKU1 (“CoV-HKU1”), isolated in Hong Kong. The virus belongs to the order Nidovirales of the family Coronaviridae, being a single-stranded RNA virus of positive polarity. Further study on nasopharyngeal aspirates from patients with community-acquired pneumonia has revealed that there are two genotypes, genotype A and genotype B, for this virus. In addition to the genomic sequences of these two genotypes, the invention provides the deduced amino acid sequences of the complete genome of the CoV-HKU1. The nucleotide sequences and deduced amino acid sequences of the CoV-HKU1 are useful in preventing, diagnosing and/or treating the infection by CoV-HKU1. Furthermore, the invention provides immunogenic and vaccine preparations using recombinant and chimeric forms as well as subunits of the CoV-HKU1 based on the nucleotide sequences and deduced amino acid sequences of the CoV-HKU1.Type: GrantFiled: May 16, 2005Date of Patent: May 13, 2008Assignee: The University of Hong KongInventors: Kwok Yung Yuen, Chiu Yat Patrick Woo, Kar Pui Susanna Lau, Kwok Hung Chan
-
Patent number: 7368114Abstract: Novel recombinant polypeptides are disclosed herein that include a CD4 polypeptide ligated at its C-terminus with a portion of an immunoglobulin comprising a hinge region and a constant domain of a mammalian immunoglobulin heavy chain. The portion or the IgG is fused at its C-terminus with a polypeptide comprising a tailpiece from the C-terminus of the heavy chain of an IgA antibody ara tailpiece from a C-terminus of the heavy chain of an IgM antibody. Also disclosed herein are methods for using these CD4 fusion proteins.Type: GrantFiled: October 24, 2002Date of Patent: May 6, 2008Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: James Arthos, Claudia Cicala, Anthony S. Fauci
-
Patent number: 7368118Abstract: Peptides are used to define epitopes that stimulate HLA-restricted cytotoxic T lymphocyte activity against hepatitis B virus antigens. The peptides are derived from regions of HBV envelope, and are particularly useful in treating or preventing HBV infection, including methods for stimulating the immune response of chronically infected individuals to respond to HBV antigens.Type: GrantFiled: February 28, 2005Date of Patent: May 6, 2008Assignee: The Scripps Research InstituteInventor: Francis V. Chisari
-
Patent number: 7361352Abstract: A chimeric, carboxy-terminal truncated hepatitis B virus nucleocapsid (HBc) protein is disclosed that contains an immunogen for inducing the production of antibodies to the influenza M2 protein. An immunogenic influenza sequence in two to four copies is preferably expressed at or near the N-terminus or in the HBc immunogenic loop sequence. The HBc chimer preferably contains an influenza-specific T cell epitope and is preferably engineered for both enhanced stability of self-assembled particles and enhanced yield of those chimeric particles. Methods of making and using the chimers are also disclosed.Type: GrantFiled: February 26, 2004Date of Patent: April 22, 2008Assignees: Acambis, Inc., Vlaams Interuniversitair Institutuut voor BiotechnologieInventors: Ashley J. Birkett, Walter Fiers
-
Patent number: 7351570Abstract: The invention concerns nucleic acid molecules derived from novel hepatitis D virus strains or isolates constituting genotypes different from known I, II and III genotypes, their fragments, corresponding proteins and their uses as diagnostic reagents. The invention also concerns a method for sensitive diagnosis of the hepatitis D virus (or delta hepatitis virus) and a method for epidemiologic monitoring of HDV-related infections.Type: GrantFiled: September 23, 2002Date of Patent: April 1, 2008Assignee: Assistance Publique-Hopitaux de ParisInventors: Paul Deny, Nadjia Radjef, Patricia Huc-Anais
-
Patent number: 7341723Abstract: A method for enhancing an immune response to a nucleic acid vaccine comprising administering to an animal a nucleic acid construct encoding a fusion protein comprising a processing component and an antigenic polypeptide of interest wherein said processing component provides heterogeneous processing of the antigenic polypeptide when the nucleic acid construct is expressed in a host cell and a resulting enhancement of the immune response. The processing component is derived from an N-terminal portion of PORF2 of Hepatitis E virus.Type: GrantFiled: September 27, 2002Date of Patent: March 11, 2008Assignee: Macfarlane Burnet Institute for Medical Research and Public Health Ltd.Inventors: Fan Li, David Andrew Anderson, Damian Francis John Purcell
-
Patent number: 7320857Abstract: Severe Acute Respiratory Syndrome (“SARS”) is a human respiratory disease of recent origin, widespread infectivity, recurring incidence, and significant mortality. Although there is abundant evidence suggesting that the coronavirus responsible for the disease (“SARS-CoV”) evolves during an outbreak, there is currently little data on the earliest strains of this coronavirus. The present invention is directed to the characterization of the genomic RNA sequences of these earliest SARS coronaviruses, to the identification of nucleotide positions within the SARS-CoV genomic RNA that are characteristic of the different evolutionary stages of the coronavirus, to kits based on these positions for use in diagnosis of the disease in patients, and for the development of vaccines to the disease based on the lowered virulence and contagiousness of these earliest strains of SARS-CoV.Type: GrantFiled: July 9, 2004Date of Patent: January 22, 2008Assignee: Chinese National Human Genome Center at ShanghaiInventors: Guoping Zhao, Rui Heng Xu, Xinwei Wu, Changchun Tu, Huai-Dong Song, Yixue Li, Jinlin Hou, Jun Xu, Jun Min
-
Patent number: 7313357Abstract: The present invention relates to a method for detection and/or genetic analysis of HBV in a biological sample, comprising hybridizing the polynucleic acids of the sample with a combination of at least two nucleotide probes, with said combination hybridizing specifically to a mutant target sequence chosen from the HBV RT pol gene region and/or to a mutant target sequence chosen from the HBV preCore region and/or to a mutant target sequence chosen from the HBsAg region of HBV and/or to a HBV genotype-specific target sequence, with said target sequences being chosen from FIG.Type: GrantFiled: June 4, 2003Date of Patent: December 25, 2007Assignee: Innogenetics N.V.Inventors: Lieven Stuyver, Rudi Rossau, Geert Maertens
-
Patent number: 7294500Abstract: The invention relates to Infectious Bursal Disease Virus (“IBDV”) and vaccines therefor. Provided are infectious recombinant Infectious Bursal Disease Virus (“rIBDV”) essentially incapable of growing in a cell that is not derived from a bursa cell, or an infectious rIBDV having retained at least part of the very virulent characteristics of a very virulent Infectious Bursal Disease Virus (“vvIBDV”).Type: GrantFiled: January 14, 2002Date of Patent: November 13, 2007Assignee: ID-Lelystad, Instituut voor Dierhouderij en Diergezondheid B.V.Inventors: Hendrik Johannis Boot, Anna Agnes H. M. ter Huurne, Bernardus Petrus H. Peeters
-
Patent number: 7282205Abstract: Chimpanzee monoclonal antibodies and antigen binding fragments including a ?1-chain CDR3 region that bind hepatitis A virus (HAV) antigen are disclosed herein. The antibodies neutralize HAV. Also disclosed are methods for using these antibodies and antigen binding fragments in the detection of hepatitis A virus, the inhibition of infection of a subject with hepatitis A virus, and in screening for agents that affect HAV.Type: GrantFiled: November 7, 2002Date of Patent: October 16, 2007Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Darren J. Schofield, Suzanne U. Emerson, Robert H. Purcell
-
Patent number: 7257365Abstract: The invention provides a method for detecting the presence of altered serum proteins in an Hepatitis B Virus (HBV)-infected patient with liver inflammation, comprising: obtaining a sample of serum from the patient; subjecting the sample to protein gel electrophoresis to separate proteins contained therein; staining proteins separated on the electrophoresis gel with silver nitrate solution; scanning the images of stained proteins into an image analysis scanner to obtain gel images; comparing the gel images to control samples of electrophoresis gels prepared from serum of normal patient and serum of HBV-infected patient with liver inflammation to determine whether the sample of serum from the patient contains specific serum proteins. This invention also provides serum protein biomarkers for the diagnosis of patients with HBV infection and liver inflammation.Type: GrantFiled: April 26, 2004Date of Patent: August 14, 2007Assignee: The University of Hong KongInventors: Qing-Yu He, Jen-Fu Chiu, George Lau, Yuan Zhou
-
Patent number: 7252984Abstract: The present invention relates to new attenuated mutant New Castle's disease La SotaNewcastle disease virus strains suitable for in ovo vaccination of avian species comprising a mutation in the gene sequences encoding the HN and/or F glycoproteins of said virus. Furthermore, the invention relates to a vaccine composition comprising said attenuated mutant Newcastle's disease La Sota virus strain, and to the use thereof for the preparation of a vaccine for in ovo vaccination of avian species against Newcastle's disease.Type: GrantFiled: October 2, 2002Date of Patent: August 7, 2007Assignee: Centrum Voor Onderzoek in Diergeneeskunde en AgrochemieInventors: Jan Mast, Guy Meulemans
-
Patent number: 7238526Abstract: Methods for efficient production of recombinant AAV employ a host cell which comprising AAV rep and cap genes stably integrated within the cell's chromosomes, wherein the AAV rep and cap genes are each operatively linked to regulatory sequences capable of directing the expression of the rep and cap gene products upon infection of the cell with a helper virus, a helper gene, and a helper gene product. A method for producing recombinant adeno-associated virus (rAAV) involves infecting such a host cell with a helper virus, gene or gene product and infecting the infected host cell with a recombinant hybrid virus or plasmid vector containing adenovirus cis-elements necessary for replication and virion encapsidation, AAV sequences comprising the 5? and 3? ITRs of an AAV, and a selected gene operatively linked to regulatory sequences directing its expression, which is flanked by the above-mentioned AAV sequences.Type: GrantFiled: September 11, 2002Date of Patent: July 3, 2007Assignee: The Trustees of the University of PennsylvaniaInventors: James M. Wilson, Guangping Gao
-
Patent number: 7232899Abstract: The present invention relates to methods for gene therapy, especially to adenovirus-based gene therapy, and related cell lines and compositions. In particular, novel nucleic acid constructs and packaging cell lines are disclosed, for use in facilitating the development of high-capacity and targeted vectors. The invention also discloses a variety of high-capacity adenovirus vectors and related compositions and kits including the disclosed cell lines and vectors. Finally, the invention discloses methods of preparing and using the disclosed vectors, cell lines and kits.Type: GrantFiled: January 14, 2000Date of Patent: June 19, 2007Assignee: The Scripps Research InstituteInventors: Daniel J. Von Seggern, Glen R. Nemerow